Literature DB >> 10208861

High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease.

Y M Kuo1, M R Emmerling, H C Lampert, S R Hempelman, T A Kokjohn, A S Woods, R J Cotter, A E Roher.   

Abstract

A previously unrecognized large pool of Abeta was discovered in freshly drawn plasma of patients diagnosed with Alzheimer's disease (AD) and non-demented control subjects. This Abeta pool was revealed after acid denaturation and chromatographic separation of plasma proteins followed by Abeta quantitation in the 4.5 kDa fractions by europium immunoassay. The mean values of Abeta42 in the AD and control individuals amounted to 236 ng/ml and 38 ng/ml, respectively. These Abeta values are on the average far higher than previously measured. Surprisingly, the circulating Abeta42 is about 16 times more abundant than Abeta40 in the AD population. Addition of Abeta to freshly drawn plasma demonstrated the rapid disappearance of Abeta epitopes, as detected by immunochemical techniques, suggesting either proteolytic degradation or Abeta sequestration. Incubation of Abeta with purified plasma proteins and lipoproteins rapidly decreases detectable levels of free Abeta suggesting epitope masking as the likely mechanism. The free and protein-bound Abetab in the circulation may represent a potential source for deposition in the cerebrovasculature and brain parenchyma of AD. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208861     DOI: 10.1006/bbrc.1999.0552

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  55 in total

Review 1.  Amyloid beta peptide membrane perturbation is the basis for its biological effects.

Authors:  J N Kanfer; G Sorrentino; D S Sitar
Journal:  Neurochem Res       Date:  1999-12       Impact factor: 3.996

2.  Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism.

Authors:  Y M Kuo; T A Kokjohn; M D Watson; A S Woods; R J Cotter; L I Sue; W M Kalback; M R Emmerling; T G Beach; A E Roher
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 3.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

4.  Soluble amyloid beta-oligomers affect dielectric membrane properties by bilayer insertion and domain formation: implications for cell toxicity.

Authors:  Gintaras Valincius; Frank Heinrich; Rima Budvytyte; David J Vanderah; Duncan J McGillivray; Yuri Sokolov; James E Hall; Mathias Lösche
Journal:  Biophys J       Date:  2008-05-30       Impact factor: 4.033

Review 5.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

6.  Atomic-resolution map of the interactions between an amyloid inhibitor protein and amyloid β (Aβ) peptides in the monomer and protofibril states.

Authors:  Moustafa Algamal; Rashik Ahmed; Naeimeh Jafari; Bilal Ahsan; Joaquin Ortega; Giuseppe Melacini
Journal:  J Biol Chem       Date:  2017-08-10       Impact factor: 5.157

7.  Progranulin protein levels are differently regulated in plasma and CSF.

Authors:  Alexandra M Nicholson; NiCole A Finch; Colleen S Thomas; Aleksandra Wojtas; Nicola J Rutherford; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; David S Knopman; Ronald C Petersen; Rosa Rademakers
Journal:  Neurology       Date:  2014-04-25       Impact factor: 9.910

8.  Physiological Aβ Concentrations Produce a More Biomimetic Representation of the Alzheimer's Disease Phenotype in iPSC Derived Human Neurons.

Authors:  Bonnie J Berry; Alec S T Smith; Christopher J Long; Candace C Martin; James J Hickman
Journal:  ACS Chem Neurosci       Date:  2018-05-22       Impact factor: 4.418

9.  Anti-amyloidogenic activity of IgGs contained in normal plasma.

Authors:  Brian O'Nuallain; Angela D Williams; Helen P McWilliams-Koeppen; Luis Acero; Alfred Weber; Hartmut Ehrlich; Hans P Schwarz; Alan Solomon
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

10.  Resolution of oligomeric species during the aggregation of Aβ1-40 using (19)F NMR.

Authors:  Yuta Suzuki; Jeffrey R Brender; Molly T Soper; Janarthanan Krishnamoorthy; Yunlong Zhou; Brandon T Ruotolo; Nicholas A Kotov; Ayyalusamy Ramamoorthy; E Neil G Marsh
Journal:  Biochemistry       Date:  2013-03-08       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.